- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
INCIVO® (Telaprevir) Approved In Europe Offering Higher Cure Rates For Genotype-1 Chronic Hepatitis C Compared To Standard Treatment
New treatment options increase chance of a cure
24 Week Incivo® (Telaprevir)-Based Regimen Effective For Majority Of Previously Untreated Genotype-1 Chronic HCV Patients
ILLUMINATE Phase 3 Study Published In New England Journal Of Medicine
Johnson & Johnson Symposium Honors 2011 Recipient Of The Dr. Paul Janssen Award For Biomedical Research
Ferrara Honored For Unlocking Key To Novel Anti-Angiogenesis Therapies
Zytiga® Approved In The European Union For Metastatic Castration-Resistant Prostate Cancer
First once-daily, oral treatment inhibits androgen production at all sources
Young Patients To Benefit From Health Canada Approval Of Remicade®* For Treatment Of Pediatric Ulcerative Colitis
Canadian Children Six To 17 Years Old Become The First Worldwide To Benefit From A New Biologic Treatment Option Approved For Chronic Inflammatory Bowel Disease
NUCYNTA® ER (Tapentadol Extended-Release Tablets) Receives FDA Approval For The Management Of Moderate To Severe Chronic Pain
Clinical Trial Data Demonstrate Efficacy, Safety and Favorable Tolerability